Back to Resource Hub Case Study

Accelerating COVID-19 Therapeutic Development in Japanese Trial

This case study demonstrates how Signant SmartSignals eCOA supported Shionogi Pharmaceuticals' Phase II/III clinical trials for a COVID-19 therapeutic drug during the pandemic.

Facing challenges of remote monitoring requirements and rapid implementation needs, Shionogi leveraged Signant's solution to enable real-time tracking of patient-reported symptoms, blood oxygenation levels, and body temperatures across 90+ sites in four countries.

Signant's flexible implementation approach enabled patient enrollment to begin within just ten weeks of trial kick-off in Japan, and only six weeks in South Korea following trial expansion.

The system's real-time monitoring capabilities and 24/7 multilingual helpdesk support ensured high-quality data through improved patient compliance, facilitating reliable assessment of the drug's efficacy and safety.

This success story illustrates how Signant's "Four S" approach — Solution, Science, Scale, and Service — provided Shionogi with the technical capabilities, evidence generation expertise, multinational support, and global project management needed to successfully conduct complex clinical research during challenging pandemic conditions.

Similar posts

Looking for more insights? Explore related resources.

BROCHURE

Signant SmartSignals eCOA Solution Overview

SEE THE BROCHURE
WHITE PAPER

Successful eCOA Depends on the Four S's

READ THE PAPER
CASE STUDY

SmartSignals eCOA Facilitates Mid-Study Amendments in an Oncology Trial

READ THE STUDY

Get notified on new marketing insights

Here mention the benefits of subscribing